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Background: Hypertrophic cardiomyopathy (HCM) is a disease of profound phenotypic and genotypic heterogeneity and the most common cause 
of sudden cardiac death (SCD) in young adults. Mutations in genes encoding myofilament proteins of the cardiac sarcomere comprise the most 
common cause of genetically mediated HCM. However the true spectrum and prevalence of mutations in these genes varies widely between different 
studies. Herein, we present the largest cohort of HCM patients genotyped to date providing insight in the true prevalence of myofilament/sarcomeric 
HCM.
Methods: Between 1999 and 2007, 1061 unrelated patients with the clinical diagnosis of HCM (60% male, age at diagnosis 44.4 ± 19 years) 
were enrolled for research-based genetic testing by PCR, DHPLC, and direct DNA sequencing of the 9 genes (ACTC1, MYBPC3, MYH7, MYL2, MYL3, 
TNNC1, TNNT2, TNNI3, TPM1) that encode the critical myofilament/sarcomeric proteins and cause myofilament/sarcomeric-HCM. Comprehensive 
phenotyping was done by review of electronic medical records and used for genotype-phenotype analyses.
Results: Overall,399 patients (38%) were genotype positive for myofilament/sarcomeric-HCM following identification of a possibly or probably 
deleterious mutation in > 1 gene. MYPBC3- and MYH7-HCM were the most common genetic subtypes (19% and 12% respectively), while the 7 other 
genes each accounted for < 1% of cases. 23/399 (7%) genotype positive patients had multiple mutations. Compared to genotype negative patients, 
genotype-positive patients were younger at diagnosis (37.1 ± 17 vs. 48.8 ± 18 years; p < 0.001), had higher mean left ventricular wall thickness 
(MLVWT, 22.5 ± 6 vs. 19.9 ± 6 mm; p < 0.001), and were more likely to have a positive family history of HCM (43% vs. 18%; p < 0.001) or SCD 
(26 % vs. 16%; p<0.05). Among patients with early onset, severe HCM defined as being diagnosed before age 40 with MLVWT > 20mm, the yield of 
genetic testing was 63%.
Conclusions: In this largest HCM cohort to date, comprehensive genotyping showed a yield of genetic testing of 38%, increased to 63% for 
patients with severe HCM. MYBPC3 and MYH7 are by far the most common genotypes with the other genes combined contributed to < 5% of HCM. 
